MEDTRONIC TRANSFORM CARDIOMYOSTIMULATOR DEVICE PHASE IV TRIAL UNDERWAY
This article was originally published in The Gray Sheet
Executive SummaryMEDTRONIC TRANSFORM CARDIOMYOSTIMULATOR DEVICE PHASE IV TRIAL UNDERWAY at 20 U.S. and foreign medical centers. The company gained FDA approval of a supplemental investigational device exemption in August for the 600-patient, randomized study of the Model SP 1005 Transform.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.